Format

Send to

Choose Destination
Otol Neurotol. 2005 Sep;26(5):1022-6.

Oral administration of prednisone to control refractory vertigo in Ménière's disease: a pilot study.

Author information

1
Department of Otolaryngology, Hospital de Especialidades del Centro Medico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.

Abstract

OBJECTIVE:

To establish whether the oral administration of moderate doses of prednisone reduces refractory vertigo in Ménière's disease.

STUDY DESIGN:

Blinded, randomized, controlled trial.

SETTING:

Tertiary referral center.

PATIENTS:

Patients with Ménière's disease with limited vertigo control (Class C) and severe disability (Scale 3).

INTERVENTIONS:

Two groups (n = 8 per group) were treated orally with either diphenidol (25 mg/d) plus acetazolamide (250 mg/48 h) (control group), or the same treatment plus prednisone (0.35 mg/kg) daily for 18 weeks (prednisone group).

MAIN OUTCOME MEASURES:

The variables evaluated were the frequency and duration of vertigo, tinnitus, aural fullness, and audiographic parameters. The clinical surveillance was performed for 12 months after prednisone withdrawal.

RESULTS:

The frequency and duration of vertigo episodes were reduced by 50% and 30%, respectively, by prednisone treatment. Prednisone-treated patients manifested a significant reduction in tinnitus. No changes were observed in aural fullness or hearing. No metabolic or infectious disorders were observed.

CONCLUSION:

Oral prednisone helps to control refractory vertigo in Ménière's disease. These preliminary data suggest that prednisone can be a good noninvasive antivertigo management regimen for these patients.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center